[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100592557":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":28,"locations":34,"responsibleParty":61,"collaborators":11,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":67,"sex":72,"minAge":73,"maxAge":11,"enrollmentInfo":74,"targetDuration":11,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":11,"overallStatus":36,"whyStopped":11,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Huashan Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"0.25mg\u002Fkg TNK group","EXPERIMENTAL",null,[13],"Drug: 0.25mg\u002Fkg TNK",{"label":15,"type":16,"description":11,"interventionNames":17},"Standard medical treatment","PLACEBO_COMPARATOR",[18],"Drug: Standard medical treatment",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"DRUG","0.25mg\u002Fkg TNK","Patients in the tenecteplase group were administered a 0.25mg\u002Fkg dose as a bolus over 5-10 seconds, followed by a 2 mL saline flush.",[9],{"type":21,"name":15,"description":26,"armGroupLabels":27,"otherNames":11},"Patients in the standard medical treatment group will receive the standard treatment selected by local doctors, including antithrombotic agents, lipid-lowering agents, antihypertensive drugs, and hypoglycemic agents. Patients would be ineligible if bridging endovascular treatment is planned at the time of randomization.",[15],[29],{"name":30,"role":31,"phone":32,"phoneExt":11,"email":33},"Xin Cheng, MD, PhD","CONTACT","+86 021-52887145","chengxin@fudan.edu.cn",[35,53],{"facility":5,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"RECRUITING","Shanghai","Shanghai Municipality","200040","China","CN",{"type":43,"coordinates":44},"Point",[45,46],121.45806,31.22222,{"lat":46,"lon":45},[49],{"name":50,"role":31,"phone":51,"phoneExt":11,"email":52},"Wei Huang","52888046","hskyc@fudan.edu.cn",{"facility":54,"status":55,"city":37,"state":11,"zip":11,"country":40,"countryCode":41,"cosmosGeoPoint":56,"geoPoint":58,"contacts":59},"Huashan Hospital, Fudan University","NOT_YET_RECRUITING",{"type":43,"coordinates":57},[45,46],{"lat":46,"lon":45},[60],{"name":30,"role":31,"phone":32,"phoneExt":11,"email":33},{"type":62,"investigatorFullName":63,"investigatorTitle":64,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Xin Cheng","Professor and Vice Chair, Department of Neurology, Huashan Hospital, Fudan University","100592557","phase-3-chinese-ischemic-stroke-beyond-45-hours-with-tenecteplase-under-optimized-non-contrast-ct-selection-100592557",false,"NCT06994975","CHinese ischEmic Stroke Beyond 4.5 Hours With TeNecteplase Under Optimized Non-Contrast CT Selection","CHESTNUT","Inclusion Criteria:\n\n1. Suspected acute ischemic stroke of anterior cerebral circulation.\n2. Last known well time \\>4.5 hours.\n3. Age ≥18 years old.\n4. Baseline NIHSS (National Institutes of Health Stroke Scale) score \\>5.\n5. Premorbid modified Rankin Scale (mRS) ≤1.\n6. Imaging criteria: Automated infarct segmentation by NCCT post-processing model indicates infarct core volume \\\u003C50 mL with no visible hypodensity in \\>1\u002F3 of the MCA territory.\n7. Informed consent signed by the patient or the patient's legally authorized representative.\n\nExclusion Criteria:\n\n1. Obvious hypodensity on NCCT deemed related with the current stroke event, with no expected benefit from thrombolysis as assessed by the investigators\n2. Endovascular thrombectomy (EVT) planned at the time of randomization\n3. Allergy to the test drug and its ingredients\n4. Rapidly improving symptoms at the discretion of the investigator\n5. Any sign of an acute intracranial hemorrhage or subarachnoid hemorrhage identified on baseline NCCT\n6. History of any intracranial hemorrhage\n7. History of ischemic stroke or major head trauma within the last 3 months\n8. History of intracranial\u002Fintraspinal surgery during the last 3 months\n9. Gastrointestinal malignancy or gastrointestinal bleeding within 21 days\n10. Known bleeding diatheses; platelets count \\\u003C 100000\u002Fmm3, international normalized ratio \\> 1.7, prothrombin time \\> 15 s, or activated partial thromboplastin clotting time \\> 40 s\n11. Treatment with a full dosage of low-molecular weighted heparin in the last 24 hours\n12. Treatment with direct thrombin inhibitors or direct factor Xa inhibitors within the previous 48 hours unless the laboratory test of coagulation function is normal\n13. Initial systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥100 mmHg\n14. Initial glucose levels \\\u003C2.8 or 22.22 mmol\u002FL\n15. Known or suspected aortic arch dissection\n\nIn addition to:\n\n1. Clinical presentation or imaging profile consistent with Moyamoya disease\u002Fsyndrome.\n2. Pregnancy or breastfeeding.\n3. Recent participation in another investigational drug or device study or registry in the past 30 days before enrollment.\n4. Any terminal illness such that the patient would not be expected to survive more than three months.\n5. Other conditions in which investigators believe that participating in this study may be harmful to the patient.","ALL","18 Years",{"count":75,"type":76},890,"ESTIMATED","INTERVENTIONAL",[79],"PHASE3","The CHESTNUT trial is a multicenter, open-label, blinded-endpoint, randomized, controlled, phase 3 trial. The primary objective of this study is to explore the efficacy and safety of the dose of 0.25 mg\u002Fkg tenecteplase (TNK) in Chinese acute ischemic stroke (AIS) patients without substantial infarction on non-contrast computed tomography (NCCT) in an extended time window.",[82],"Acute Ischemic Stroke","2025-12-22",{"date":85,"type":86},"2025-12-30","ACTUAL",{"date":88,"type":86},"2025-11-03",{"date":90,"type":76},"2028-06",{"name":5,"class":6},2]